- Bridging Internal and External Exposure: Leveraging Human Biomonitoring Data Through Physiologically Based Kinetic Modeling Toward Next-Generation Risk Assessment
-
Stars at Night Ballroom B4‚ Convention Center
Chair: Paul Price, Risk Science International, Canada
Co-Chair: Lara Lamon, ESQlabs GmbH, Germany
Primary Endorser: Biological Modeling Specialty Section
Endorser(s): Computational Toxicology Specialty SectionUnderstanding how much of a chemical actually reaches target tissues and what effects this may cause to human health is at the heart of Next-Generation Risk Assessment (NGRA), a human-relevant, exposure-led, hypothesis-driven risk assessment approach, designed to prevent harm. Traditional approaches have so far relied heavily on animal-derived data, but confidence in these methods has been eroding. In fact, animal models can be poorly suited for advancing human health risk assessment, both because of physiological differences, as is well illustrated in inhalation toxicity, where respiratory anatomy and breathing dynamics differ substantially between species, and because modes of action for specific chemicals can be highly diverse between species. Beyond this, the application of assessment factors across species is perceived as a weakness rather than a conservative safeguard. Furthermore, ethical concerns around animal testing have grown considerably, while on the scientific side, mounting evidence that animal models often fail to predict human outcomes has prompted a fundamental rethinking of how we assess chemical safety. Meeting this challenge depends not only on new sources of human data but also on the development of new biological modeling methodologies that translate that data into quantitative, mechanistic, and decision-ready insights.
The availability of human biomonitoring (HBM) data can streamline human health risk assessment as they provide direct evidence of real-world chemical exposures in humans, capturing the complexity of multiple exposure routes, lifestyle factors, and population variability. Available human biomonitoring data provide a useful resource in NGRA as an indicator of the total exposure to a population. Physiologically based pharmacokinetic (PBK) models, in turn, allow us to interpret those measurements mechanistically, linking what is measured in blood, urine, or other biological matrices to what actually happens inside the body over time. Together, these tools offer a powerful and human-relevant framework for estimating internal doses more accurately and with greater confidence than conventional methods alone. They can be integrated in three complementary ways in support of NGRA: (i) in reverse dosimetry, HBM measurements verify whether calculated or measured external exposures are consistent with real-world internal dose levels; (ii) in forward dosimetry, PBK model predictions of internal concentrations can be evaluated against HBM data to confirm their biological plausibility, and those concentrations can then feed into QIVIVE to compare predicted internal doses with in vitro points of departure, ultimately supporting the derivation of human-relevant, animal-free health-based reference values expressed directly in biomarker space; and (iii) real-world HBM cohort data can parameterize and validate PBK models for specific populations, capturing interindividual variability across life stages and sensitive groups in ways that generic models or traditional approaches cannot. Together, these three applications enable triangulation between external exposure, internal dose, and in vitro effect concentrations within a coherent NGRA framework.
This session will showcase how this integrated approach can be applied across vulnerable life stages where physiological changes like altered body composition, cardiac output, and kidney and liver function, meaningfully shift how chemicals are absorbed, distributed, metabolized and eliminated. Pregnant women represent a particularly compelling case: developmental toxicity endpoints are inherently difficult to measure directly in humans, making mechanistic modeling informed by biomonitoring data especially valuable for understanding fetal exposure and assessing risks during this delicate life stage. The presentations will address both the scientific opportunities and the practical challenges of applying PBK models in these vulnerable populations, including data quality and availability, model uncertainty and parameterization, and the steps needed to build regulatory confidence in these methods for informing policy and protecting susceptible groups.
By moving beyond animal-based external dose metrics and toward human-centered, data-informed modelling, this session contributes to the broader vision of NGRA: one that is more relevant, more transparent, and better equipped to protect human health. Central to that contribution is the advancement of new biological modeling methodologies and novel frameworks that make human-relevant, animal-free risk assessment achievable in practice. Attendees will gain insights into how HBM data can evaluate or challenge conventional exposure assumptions, and the practical steps how PBK modeling can bridge uncertainties in vulnerable populations, and the practical steps toward integrating these approaches into regulatory frameworks.
IAT ITS Designation: Innovations in Applied Toxicology (IAT)
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
